Skip to main content
ARECOR THERAPEUTICS PLC logo

ARECOR THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AREC ISIN · GB00BMWLM973 LEI · 98450093D12I3A8DDD58 IL Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2025-05-06 Report Publication Anno…
Country GB United Kingdom
Listing IL AREC

About ARECOR THERAPEUTICS PLC

https://arecor.com/

Arecor Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing enhanced therapeutic medicines. The company utilizes its proprietary Arestat® technology platform, a formulation science designed to improve the properties of proteins and peptides, enabling superior drug product profiles. Arecor's business model involves two approaches: developing an internal portfolio of proprietary products and partnering with pharmaceutical and medtech companies to enhance their therapeutic offerings. The company's in-house development pipeline is primarily focused on advancing treatments for diabetes and other cardiometabolic diseases, including next-generation insulin candidates.

Recent filings

Filing Released Lang Actions
Posting of 2024 Annual Report and Notice of AGM
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3307 chars) released via RNS (London Stock Exchange news service). The title explicitly states: 'Posting of Arecor 2024 annual report and notice of AGM'. The body confirms that the 'Annual Report and Accounts for the year ended 31 December 2024' and the 'Notice of the Annual General Meeting ("AGM")' have been published and posted to shareholders, and provides a link to view/download them. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces the publication of a report (like the Annual Report or AGM notice) rather than containing the full report itself, it should be classified as a Report Publication Announcement (RPA). Since this document announces both the Annual Report and the AGM notice, RPA is the most appropriate classification for the announcement itself.
2025-05-06 English
Arecor to present on Investor Meet Company
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) regarding an upcoming investor presentation event. It does not contain the actual financial report or presentation slides, but rather serves as a notification to shareholders about a scheduled event to discuss previously released results. According to the 'Menu vs Meal' rule, this is a notification/announcement, and since it does not fit into specific categories like 'Report Publication Announcement' (which usually refers to the release of a document) or 'Investor Presentation' (which is the presentation itself), it falls under the general 'Regulatory Filings' (RNS) category as a corporate announcement.
2025-04-24 English
Grant of Options and PDMR Dealing
Director's Dealing Classification · 100% confidence The document is an official announcement regarding the grant of share options to a Person Discharging Managerial Responsibilities (PDMR), specifically the Chief Financial Officer, David Ellam. It includes the required Market Abuse Regulation (MAR) disclosure table detailing the transaction. This falls squarely under the definition of 'Director's Dealing' (DIRS), which covers reports of share transactions or option grants involving company directors and executives.
2025-04-23 English
Final results for 2024
Earnings Release Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from Arecor Therapeutics PLC regarding its 'FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024'. It contains financial highlights, operational reviews, and a CEO/Chair statement. While it provides a summary of financial performance, it explicitly states that the full 'Annual Report and Accounts' will be posted to shareholders in due course. Therefore, this document is an Earnings Release (ER) announcing the preliminary results, rather than the full Annual Report (10-K) itself. FY 2024
2025-04-22 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) titled 'NOTICE OF RESULTS'. It informs the market that the company will announce its audited final results on a future date (22 April 2025) and provides details about an upcoming briefing. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore falls under the Report Publication Announcement (RPA) category.
2025-04-10 English
Collaboration with global pharmaceutical partner
M&A Activity Classification · 99% confidence The document is a formal announcement released via RNS (Regulatory News Service) of the London Stock Exchange, indicated by the 'RNS Number' header and the concluding boilerplate text referencing RNS and the FCA. The content details a new collaboration agreement for formulation studies, which is a significant business development event. Since this is a general, material announcement that doesn't fit the specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), and it is clearly a regulatory news wire release, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2025-03-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.